arGentis Pharmaceuticals, LLC Files Patent on Nucleic Acid Sequences and Polymorphisms Predictive of Patient Responses to ARG201 an Immunotherapy for Late Phase Systemic Sclerosis

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that it has filed a patent application for Nucleic Acid Sequences highly associated with the inability of oral immune tolerance to be induced in some systemic sclerosis (SSc) patients. As explained in the patent application, the identified sequences predict which patients can respond to ARG201, an immunotherapy that induces oral immune tolerance in patients with Late Phase diffuse cutaneous systemic sclerosis.